Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy

Leukemia volume 19, pages 1–3 (2005)Cite this article

TO THE EDITOR

The efficacy of arsenic trioxide (ATO) in relapsed patients with acute promyelocytic leukemia (APL) has been established. ATO can be used as a single agent and induces complete remission with only minimal myelosuppression. Several reports showed that 80–85% of relapsed APL patients achieved complete remission with ATO alone. The 18-month overall survival was 42–66%.1, 2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.

    Article  CAS  Google Scholar 

  2. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617–622.

    Article  CAS  Google Scholar 

  3. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514–1516.

    Article  CAS  Google Scholar 

  4. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881–885.

    Article  CAS  Google Scholar 

  5. Goldberg MA, Glass GA, Cunningham JM, Bunn HF . The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972–7976.

    Article  CAS  Google Scholar 

  6. Ebert BL, Bunn HF . Regulation of the erythropoietin gene. Blood 1999; 94: 1864–1877.

    CAS  Google Scholar 

  7. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE . Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 5680–5684.

    Article  CAS  Google Scholar 

  8. Imagawa S, Yamamoto M, Miura Y . Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997; 89: 1430–1439.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Graduate School of Medicine, Nagoya University, Showa-ku, Nagoya, Japan

    T Kajiguchi, K Yamamoto, M Sawa, N Emi & T Naoe

Authors
  1. T Kajiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Sawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Emi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Kajiguchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kajiguchi, T., Yamamoto, K., Sawa, M. et al. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy. Leukemia 19, 1–3 (2005). https://doi.org/10.1038/sj.leu.2403635

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403635

Search

Advanced search

Quick links